Ładuje się......
Combination Therapies Targeting HDAC and IKK in Solid Tumors
The rationale for developing histone deacetylase (HDAC) inhibitors (HDACi) as anti-cancer agents was based on their ability to induce apoptosis and cell cycle arrest in cancer cells. However, while HDACi have been remarkably effective in treatment of hematological malignancies, clinical studies with...
Zapisane w:
| Wydane w: | Trends Pharmacol Sci |
|---|---|
| Główni autorzy: | , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
2017
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5818305/ https://ncbi.nlm.nih.gov/pubmed/29233541 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tips.2017.11.008 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|